Korea South
Alteogen, a leading biopharmaceutical company founded in 2008, is listed on the KOSDAQ stock exchange (KRX:196170). Based in South Korea, it is reshaping the future of medical treatments with a suite of proprietary platform technologies designed to enhance the efficacy and longevity of biologic medicines.
Central to Alteogen's innovation is its Hybrozyme™ technology, a breakthrough in human hyaluronidase that significantly improves drug absorption through subcutaneous injections. This is complemented by its NexP™ fusion technology, which extends the half-life of therapeutic proteins, advancing treatments for conditions such as diabetes and hemophilia.
Moreover, Alteogen's NexMab™ ADC technology is pioneering targeted cancer therapies, focusing on breast, gastric, and ovarian cancers, enhancing therapeutic efficacy while minimizing side effects. Their dedication to biosimilar development is further supported by established cell line processes and analytical methods.
